• Level 1 evidence from the MAF Test® analyses of the NSABP-B34 landmark clinical trial confirmed clinical utility of the MAF Test® for selection of early-stage breast cancer patients that benefit from adjuvant clodronate treatment to prevent metastasis.
  • Data published in Journal of National Cancer Institute, Cancer Spectrum.
  • MAF negative status of patients who were treated with clodronate in the adjuvant setting was predictive of significantly improved disease-free survival (primary endpoint) and overall survival (key secondary endpoint).
  • Results confirm the company’s previous data (AZURE trial analyses) on its proprietary MAF Test® published in Lancet Oncology in 2018.

More information: http://www.inbiomotion.com/media/upload/pdf/210930-pr-maf-test-english_163274245220.pdf

Subscribe to Directory
Write an Article

Recent News

¿Por qué no es recomendable llevar la ...

La mejor actitud que podemos adoptar es la de trat...

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Telum Therapeutics Secures €18 Million...

by Telum Therapeutics

Telum Therapeutics, a biotechnology company leveraging proprietary met...

Photos Stream